KDR and neoplasm: For ES patients, the CABONE trial noted that the majority of ES patients treated experienced tumor shrinkage, and the ORR was among the highest to have been observed with a tyrosine kinase inhibitor targeting the VEGFR2 pathway in solid tumors, with the exception of renal cell carcinoma, which has a high sensitivity to drugs targeting the VEGR pathway (16).